Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

October 31, 2012

Conditions
Advanced Melanoma
Interventions
DRUG

Ipilimumab

Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks

DRUG

Carboplatin

Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks

DRUG

Paclitaxel

Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks

DRUG

Dacarbazine

Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks

Trial Locations (4)

10021

Memorial Sloan Kettering Cancer Center, New York

28204

Blumenthal Cancer Center, Carolinas Medical Center, Charlotte

33612

H Lee Moffit Cancer Cnt And Res Inst, Tampa

90025

The Angeles Clinic & Research Inst., Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medarex

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY